For this trial, patients with metastatic urothelial carcinoma whose disease had progressed after platinum-based therapy or were cisplatin ineligible received avelumab 10 mg/kg Q2W. Tumors were assessed every 6 weeks by independent review (RECIST v1.1). Endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety (NCI CTCAE v4.0), and tumor PD-L1 expression. The Kaplan-Meier method was used to estimate DOR, PFS, and OS. As of September 2016, 249 patients had received avelumab and were followed for ≥6 month (median 13.6 months); 43 patients (17.3%) remained on treatment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In summary, in this updated analysis of the JAVELIN study for patients with metastatic urothelial carcinoma, avelumab showed durable clinical activity and had a manageable and tolerable safety profile irrespective of PD-L1 expression. Importantly, a phase III trial of avelumab as maintenance therapy after first-line platinum-based therapy for advanced urothelial carcinoma is ongoing.
Speaker: Andrea B. Apolo, National Cancer Institutde, Bethesda, United States of America
Co-Authors: J. Ellerton (Las Vegas, United States of America) J. R. Infante (Nashville, United States of America) M. Agrawal (Rockville, United States of America) M. S. Gordon (Scottsdale, United States of America) R. Aljumaily (Oklahoma City, United States of America) C. D. Britten (Charleston, United States of America) L. Dirix (Antwerpen, Belgium) K. Lee (Seongnam, Korea, Republic of) M. H. Taylor (Portland, United States of America) P. Schöffski (Leuven, Belgium) D. Wang (Detroit, United States of America) A. Ravaud (Bordeaux Cedex, France) A. Gelb (Billerica, United States of America) J. Xiong (Billerica, United States of America) G. Rosen (Billerica, United States of America) M. R. Patel (Sarasota, United States of America)
Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre, Twitter: @zklaassen_md at the European Society for Medical Oncology Annual Congress - September 8 - 12, 2017 - Madrid, Spain
Heery CR, O’Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): A phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017;18(5):587-598.